Cargando…

FAT1: a potential target for monoclonal antibody therapy in colon cancer

BACKGROUND: Colorectal cancer (CRC) is one of the major causes of cancer-associated mortality worldwide. The currently approved therapeutic agents have limited efficacy. METHODS: The atypical cadherin FAT1 was discovered as a novel CRC-associated protein by using a monoclonal antibody (mAb198.3). FA...

Descripción completa

Detalles Bibliográficos
Autores principales:	Pileri, Piero, Campagnoli, Susanna, Grandi, Alberto, Parri, Matteo, De Camilli, Elisa, Song, Chaojun, Ganfini, Luisa, Lacombe, Aurelien, Naldi, Ilaria, Sarmientos, Paolo, Cinti, Caterina, Jin, Boquan, Grandi, Guido, Viale, Giuseppe, Terracciano, Luigi, Grifantini, Renata
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2016
Materias:	Translational Therapeutics
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4931367/ https://www.ncbi.nlm.nih.gov/pubmed/27328312 http://dx.doi.org/10.1038/bjc.2016.145

Ejemplares similares

ERMP1, a novel potential oncogene involved in UPR and oxidative stress defense, is highly expressed in human cancer
por: Grandi, Alberto, et al.
Publicado: (2016)

Negatively charged AuNP modified with monoclonal antibody against novel tumor antigen FAT1 for tumor targeting
por: Fan, Li, et al.
Publicado: (2015)

TCTN2: a novel tumor marker with oncogenic properties
por: Cano-Rodriguez, David, et al.
Publicado: (2017)

The development and characterisation of porphyrin isothiocyanate–monoclonal antibody conjugates for photoimmunotherapy
por: Hudson, R, et al.
Publicado: (2005)

Expanding the use of monoclonal antibody therapy of cancer by using ionising radiation to upregulate antibody targets
por: Wattenberg, M M, et al.
Publicado: (2014)

Radiosensitisation of U87MG brain tumours by anti-epidermal growth factor receptor monoclonal antibodies
por: Diaz Miqueli, A, et al.
Publicado: (2009)

Human monoclonal antibodies targeting carbonic anhydrase IX for the molecular imaging of hypoxic regions in solid tumours
por: Ahlskog, J K J, et al.
Publicado: (2009)

Targeting ADAM-17 with an inhibitory monoclonal antibody has antitumour effects in triple-negative breast cancer cells
por: Caiazza, F, et al.
Publicado: (2015)

Strategies for clinical development of monoclonal antibodies beyond first-in-human trials: tested doses and rationale for dose selection
por: Viala, Marie, et al.
Publicado: (2018)

Angiogenesis in a human neuroblastoma xenograft model: mechanisms and inhibition by tumour-derived interferon-γ
por: Ribatti, D, et al.
Publicado: (2006)

Population pharmacokinetics of the humanised monoclonal antibody, HuHMFG1 (AS1402), derived from a phase I study on breast cancer
por: Royer, B, et al.
Publicado: (2010)

Engineering and characterisation of chimeric monoclonal antibody 806 (ch806) for targeted immunotherapy of tumours expressing de2-7 EGFR or amplified EGFR
por: Panousis, C, et al.
Publicado: (2005)

Targeted killing of colorectal cancer cell lines by a humanised IgG1 monoclonal antibody that binds to membrane-bound carcinoembryonic antigen
por: Conaghan, P J, et al.
Publicado: (2008)

HGS-ETR1, a fully human TRAIL-receptor 1 monoclonal antibody, induces cell death in multiple tumour types in vitro and in vivo
por: Pukac, L, et al.
Publicado: (2005)

Epidermal growth factor receptor double targeting by a tyrosine kinase inhibitor (Iressa) and a monoclonal antibody (Cetuximab). Impact on cell growth and molecular factors
por: Fischel, J-L, et al.
Publicado: (2005)

Meta-analysis of BRAF mutation as a predictive biomarker of benefit from anti-EGFR monoclonal antibody therapy for RAS wild-type metastatic colorectal cancer
por: Rowland, A, et al.
Publicado: (2015)

Multiple mechanisms underlie defective recognition of melanoma cells cultured in three-dimensional architectures by antigen-specific cytotoxic T lymphocytes
por: Feder-Mengus, C, et al.
Publicado: (2007)

Enhancement of the antitumor activity of ionising radiation by nimotuzumab, a humanised monoclonal antibody to the epidermal growth factor receptor, in non-small cell lung cancer cell lines of differing epidermal growth factor receptor status
por: Akashi, Y, et al.
Publicado: (2008)

Prognostic and predictive value of TOPK stratified by KRAS and BRAF gene alterations in sporadic, hereditary and metastatic colorectal cancer patients
por: Zlobec, I, et al.
Publicado: (2010)

PD-1 and PD-L1 expression in molecularly selected non-small-cell lung cancer patients
por: D'Incecco, A, et al.
Publicado: (2015)

Lurbinectedin reduces tumour-associated macrophages and the inflammatory tumour microenvironment in preclinical models
por: Belgiovine, Cristina, et al.
Publicado: (2017)

PD-L1 mRNA expression in plasma-derived exosomes is associated with response to anti-PD-1 antibodies in melanoma and NSCLC
por: Del Re, Marzia, et al.
Publicado: (2018)

Effects of oestrogens and anti-oestrogens on normal breast tissue from women bearing BRCA1 and BRCA2 mutations
por: Bramley, M, et al.
Publicado: (2006)

Antitumour activity of trabectedin in myelodysplastic/myeloproliferative neoplasms
por: Romano, Michela, et al.
Publicado: (2017)

Supporting Data for Multifunctional all-in-one drug delivery systems for tumor targeting and sequential release of three different anti-tumor drugs
por: Wu, Guowei, et al.
Publicado: (2016)

Identification of biomarkers for the antiangiogenic and antitumour activity of the superoxide dismutase 1 (SOD1) inhibitor tetrathiomolybdate (ATN-224)
por: Doñate, F, et al.
Publicado: (2008)

Interactions between microenvironment and cancer cells in two animal models of bone metastasis
por: Blouin, S, et al.
Publicado: (2008)

Collagenase-2 (matrix metalloproteinase-8) plays a protective role in tongue cancer
por: Korpi, J T, et al.
Publicado: (2008)

Immunisation with ‘naïve’ syngeneic dendritic cells protects mice from tumour challenge
por: Grimshaw, M J, et al.
Publicado: (2008)

CD44(+)CD24(−) prostate cells are early cancer progenitor/stem cells that provide a model for patients with poor prognosis
por: Hurt, E M, et al.
Publicado: (2008)

Regulation of apoptosis-inducing factor-mediated, cisplatin-induced apoptosis by Akt
por: Yang, X, et al.
Publicado: (2008)

20(S)-25-methoxyl-dammarane-3β, 12β, 20-triol, a novel natural product for prostate cancer therapy: activity in vitro and in vivo and mechanisms of action
por: Wang, W, et al.
Publicado: (2008)

Double inhibition of XIAP and Bcl-2 axis is beneficial for retrieving sensitivity of renal cell cancer to apoptosis
por: Bilim, V, et al.
Publicado: (2008)

Inhibition of mTOR pathway by everolimus cooperates with EGFR inhibitors in human tumours sensitive and resistant to anti-EGFR drugs
por: Bianco, R, et al.
Publicado: (2008)

Combined expression of caveolin-1 and an activated AKT/mTOR pathway predicts reduced disease-free survival in clinically confined renal cell carcinoma
por: Campbell, L, et al.
Publicado: (2008)

Growth inhibition of non-small cell lung cancer cells by AP-1 blockade using a cJun dominant-negative mutant
por: Shimizu, Y, et al.
Publicado: (2008)

CYP1B1 expression is induced by docetaxel: effect on cell viability and drug resistance
por: Martinez, V G, et al.
Publicado: (2008)

Erythropoietin receptor transcription is neither elevated nor predictive of surface expression in human tumour cells
por: Sinclair, A M, et al.
Publicado: (2008)

The involvement of FOXO1 in cytotoxic stress and drug-resistance induced by paclitaxel in ovarian cancers
por: Goto, T, et al.
Publicado: (2008)

Activity of lapatinib a novel HER2 and EGFR dual kinase inhibitor in human endometrial cancer cells
por: Konecny, G E, et al.
Publicado: (2008)

Cannot write session to /tmp/vufind_sessions/sess_845b2tjajkokpaiv5dujtvaeme